Cell-free tumor DNA analysis in advanced or metastatic breast cancer patients: mutation frequencies, testing intention, and clinical impact
The high prevalence of somatic alterations in <i>TP53, PIK3CA, ESR1</i>, and <i>BRCA1/2</i> genes, identified by ctDNA genotyping, highlights their potential as biomarkers for targeted therapies. Detection of specific mutations affected treatment decisions, such as eligibility for alpelisib, and might further facilitate treatment with e.g. elacestrant or capiversatib in future treatment lines.
Authors
- Iris Faull (ORCID: https://orcid.org/0000-0001-6005-077X)
- Carolin C. Hack (ORCID: https://orcid.org/0000-0002-2426-7020)
- Matthias Ruebner (ORCID: https://orcid.org/0000-0002-2408-1138)
- Patrick Ziegler
- Theresa Link (ORCID: https://orcid.org/0000-0002-2229-7867)
- Hanna Huebner (ORCID: https://orcid.org/0000-0001-6889-1493)
- Peter A. Fasching (ORCID: https://orcid.org/0000-0003-4885-8471)
- Sara Y. Brucker (ORCID: https://orcid.org/0000-0001-5162-1542)
- Sarah Lehle
- D. Wallwiener (ORCID: https://orcid.org/0000-0002-4635-5283)
- Eugen Ruckhäberle
- Erik Belleville
- Matthias W. Beckmann (ORCID: https://orcid.org/0000-0002-8441-693X)
- Pauline Wimberger (ORCID: https://orcid.org/0000-0002-7380-577X)
- Sabrina Uhrig
- Hans Tesch (ORCID: https://orcid.org/0000-0001-7839-4917)
- Tanja Fehm (ORCID: https://orcid.org/0000-0002-4926-0108)
- Andreas Schneeweiß (ORCID: https://orcid.org/0000-0002-2429-4512)
- Elena Laakmann
- Marcus Hausch
- Volkmar Müller (ORCID: https://orcid.org/0000-0002-6386-0900)
Institutions
- Universität Hamburg (DE)
- German Cancer Research Center (DE)
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Heidelberg University (DE)
- Helmholtz-Zentrum Dresden-Rossendorf (DE)
- University Hospital Heidelberg (DE)
- Cardiovascular Center Bethanien (DE)
- Düsseldorf University Hospital (DE)
- Guardant (United States) (US)
- German Cancer Society (DE)
- University Medical Center Hamburg-Eppendorf (DE)
- National Center for Tumor Diseases (DE)
- Cancer Research Center (US)
- Comprehensive Cancer Center Erlangen (DE)
- Clovis Oncology (United Kingdom) (GB)
- University Hospital Carl Gustav Carus (DE)
- Deutsches Konsortium für Translationale Krebsforschung (DE)
- Heinrich Heine University Düsseldorf (DE)
- Technische Universität Dresden (DE)
- University of Tübingen (DE)
Publication Details
- Journal
- Precision Clinical Medicine
- Published
- 2024-12-24
- DOI
- https://doi.org/10.1093/pcmedi/pbae034
- Citations
- 4
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 1.14
Funders
- Pfizer
- AstraZeneca
- Novartis
- Roche
- Celgene
- Hexal AG
- Daiichi-Sankyo
- Eisai